Lumi Becomes First Site Activated for DESTINY-Lung06 Trial
Lumi is proud to share that we are the very first site activated for the DESTINY-Lung06 clinical trial. This marks an exciting milestone for our team as we take part in a global study designed to explore new options for patients with non-small cell lung cancer (NSCLC).
Being the first site to open means Lumi is at the forefront of this important research effort. Our team has worked closely with study sponsors and investigators to reach this stage, and we are honored to be incorporated into a trial that holds so much promise for people facing advanced lung cancer.
About the Study
The DESTINY-Lung06 trial is evaluating a potential new treatment for people with untreated, locally advanced, or metastatic non-squamous NSCLC. The goal is to see whether the investigational therapy can help patients live longer without their cancer progressing, while also studying its safety. With hundreds of participants expected worldwide, this trial is an important step in the ongoing search for more effective treatment options.
Lumi’s Role
As the first activated site, Lumi is ready to begin welcoming participants and guiding them through the study process. Our team takes pride in ensuring patients feel supported and informed at every step. From discussing eligibility and answering questions to overseeing treatments and follow-up care, we are committed to making participation as clear and accessible as possible.
Lumi is increasing screening efforts to be the first to enroll an identified patient. This milestone will not only mark progress for the trial but also represent Lumi’s direct contribution to advancing cancer research.
Looking Ahead
Taking part in DESTINY-Lung06 reflects Lumi’s dedication to being involved in studies that matter. By working alongside international partners and leading researchers, we are proud to stand at the very beginning of this journey. Our team looks forward to contributing to the knowledge this trial will generate and to supporting patients who choose to participate.
We are excited for what lies ahead — and honored to be part of this important work.